Core Viewpoint - The company, Olin Bio (688319.SH), is progressing towards a dual listing in Hong Kong, which could enhance its capital structure and international presence, while facing regulatory uncertainties regarding the approval process [1][2]. Stock Performance - As of February 13, 2026, Olin Bio's A-share price closed at 27.13 yuan, up 4.59%, with a trading volume of 255 million yuan and a turnover rate of 2.29% [1]. Strategic Advancement - The company aims to leverage the Hong Kong listing to accelerate its "bring in" (international patents and talent) and "go out" (global sales and technology transfer) strategies, focusing on differentiated areas such as superbug vaccines and adult vaccines [2]. - In November 2025, the company received a "satisfactory compliance" rating from the Philippines FDA, facilitating entry into the Southeast Asian market, and established a vaccine production partnership with Griffith University in Australia [2]. Project Development - The proceeds from the Hong Kong listing will be allocated to the clinical development of the rHPV (Helicobacter pylori) vaccine, expansion of the III phase clinical trials for the golden staph vaccine, and upgrades to production facilities [3]. - The restructured golden staph vaccine has completed enrollment of 6,000 cases for the III phase clinical trial, with complete data expected in the first half of 2026; the quadrivalent influenza virus split vaccine (MDCK cells) commenced its III phase clinical trial in October 2025 [3]. Future Development - The Hong Kong listing is anticipated to attract international investors, broadening financing channels, which is particularly beneficial for the long-term investment required in innovative vaccine research and development [4]. - A dual listing is expected to enhance the company's international visibility, promoting business development collaborations and expansion into overseas markets [5].

Leadership Change - Sanofi has announced the appointment of Belén Garijo as the new CEO, succeeding Paul Hudson, whose contract will not be renewed [1] - Garijo, currently the CEO of Merck KGaA, will assume her new role on April 29, 2026, after a five-year tenure at Merck KGaA [2] Financial Performance - Sanofi's vaccine revenue dropped by 5% in 2025, generating €7.9 billion compared to €8.3 billion in 2024, while overall net sales grew by 9.9% at constant exchange rates to reach €43.6 billion ($51.7 billion) [4] - The company is preparing for the loss of patent protection for Dupixent, which generated €14.7 billion last year [5] Challenges and Pipeline Issues - Sanofi is facing challenges in the US vaccine sector due to policy changes under the Trump administration, impacting immunization recommendations and new candidate approvals [3] - Recent pipeline disappointments include FDA rejections and failures in multiple sclerosis treatments, as well as mixed results for COPD candidates [6] Strategic Focus - Garijo's primary focus will be on enhancing the productivity, governance, and innovation capacity of Sanofi's R&D [7]

Group 1 - Company Changda Biological announced that its wholly-owned subsidiary, Changda Biological (Benxi) Co., Ltd., received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine [1] - The approval highlights the long and uncertain development cycle of vaccine products, which may be influenced by various factors [1] Group 2 - Investors should exercise caution and consider investment risks associated with the vaccine development process [1] - Notable investments in the company include a joint investment of 1 billion yuan each from prominent investors Ge Weidong and Fang Wenyuan, leading to a significant increase in the company's stock price [1]

经济观察网绿竹生物-B(02480.HK)是北京绿竹生物技术股份有限公司的上市主体，专注于疫苗及治疗性 生物制剂研发，核心产品为重组带状疱疹候选疫苗LZ901。该公司产品尚未商业化，收入主要依赖政府 补助，近期研发重心向后期临床及商业化转移。 近期事件 业绩经营情况 公司定期发布股份变动月报表(如最近一期截至2025年12月31日的报表于2026年1月7日披露)，未来新报 表的发布可能反映股东结构变化。2024年财务数据显示研发开支1.35亿元，税前亏损1.68亿元(同比收窄 32.5%)。投资者可关注2025年全年业绩公告，以评估经营改善情况。 公司状况 华证指数最新ESG评级(2025年10月31日)为BB，行业排名第25。未来若评级调整，可能影响机构投资者 关注度。 以上内容基于公开资料整理，不构成投资建议。 LZ901的生物制品许可申请(BLA)于2025年2月获国家药监局受理，目前处于正常审评阶段。作为核心管 线，其审评结果及后续商业化进程是市场关注焦点。 公司项目推进 公司临床前在研产品已增至六款，包括重组HSV-1疫苗(针对口腔疱疹)和重组HSV-2疫苗(针对生殖器疱 疹)。未来可能披露这些管线 ...

万泰生物董事长邱子欣拟通过集中竞价方式进行减持，而减持所得股份将全部捐赠给厦门大学教育发展基金会（以下简称厦大基金会） 和福建省厦门第一中学（以下简称厦门一中）。邱子欣通过减持方式进行捐赠的行为，引发投资者和《每日经济新闻》记者（以下简称 每经记者）的关注。 万泰生物成立于1991年，致力于诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司主要业务分为体外诊断及疫苗两大类领域。万 泰生物的实际控制人为中国首富钟睒睒，其持有公司73.49%的股份。 在HPV疫苗领域，万泰生物实力雄厚，其自主研发的二价HPV疫苗（馨可宁）于2019年上市，是国内首个国产二价HPV疫苗，打破了国 外产品垄断；2025年，其九价HPV疫苗（馨可宁9）获批上市，成为国内首个国产九价HPV疫苗。 2026年2月9日晚，万泰生物发布了董事集中竞价减持股份计划公告。该公告显示，公司董事长邱子欣计划于2026年3月12日至2026年6月 11日期间，减持不超过500万股公司股份（不超过公司总股本的0.3954%）。截至目前，邱子欣持有万泰生物3.5469%的股份。 在发布董事长拟减持公告后，万泰生物股价连续三天小幅收跌。截至2026年2月12 ...

Industry Overview - The overall number of vaccine batch approvals in 2025 is projected to be 3,793, representing a year-on-year decline of 11.3%, primarily due to significant decreases in approvals for polio, meningitis, encephalitis, and measles-mumps-rubella vaccines [2][4] - Key vaccines expected to be approved in 2025 include Consonance's PCV13 and Wantai's 9-valent HPV vaccine, with several others in the review stage [1][4] Vaccine Development Pipeline - The RSV vaccine development is competitive among domestic companies, focusing on mRNA and recombinant protein technologies [1] - The shingles vaccine has four products in the application stage, indicating a rich pipeline [1] - Consonance's PCV13 has been approved, enhancing its product pipeline [1] - Wantai's 9-valent HPV vaccine is the first domestically produced vaccine to be approved [1] - Two human diploid rabies vaccines have been approved, with multiple products submitted for approval [1] - The meningitis vaccine pipeline is concentrated on MCV4, with a five-valent meningococcal vaccine from Sinovac entering clinical phase I [1] - The flu vaccine market has several products approved, with many in clinical stages [1] - Multi-valent vaccines have fewer products on the market, but several companies are pursuing differentiated strategies [1] Company-Specific Insights - Zhifei Biological's vaccine batch approvals are expected to decline, with a significant drop in agency products, while several self-developed products are nearing market launch [4] - Kangtai Biological anticipates a slight decrease in batch approvals, with the varicella vaccine contributing to new growth, and multiple vaccines in the application stage [4] - Watson Biological expects a 16% year-on-year decline in batch approvals, with RSV and shingles mRNA vaccines approved for clinical trials [4] - Wantai Biological has seen a significant increase in 2-valent HPV batch approvals, with the 9-valent HPV vaccine approved for market [4] - Kangxino Biological's MCV4 batch approvals are expected to continue growing, with PCV13 approved for market [4] - Kanghua Biological's human diploid rabies vaccine batch approvals are projected to decline, while the acquisition of Namixin aims to expand its mRNA technology platform [4] - Olin Biological anticipates significant growth in tetanus batch approvals, with data from its pneumococcal vaccine expected in the first half of 2026 [4] - Baike Biological expects a 42% year-on-year decline in vaccine batch approvals, with a liquid nasal spray flu vaccine approved [4] Investment Recommendations - Companies with strong self-research capabilities and innovative vaccine pipelines, such as Kangtai Biological, Kanghua Biological, Kangxino Biological, and Olin Biological, are recommended for investment focus, especially those with products nearing market launch [4]

Summary of the Conference Call for Bio Co., Ltd. Industry and Company Overview - The conference call focused on Bio Co., Ltd., specifically its developments in the African Swine Fever (ASF) vaccine sector, which is a critical area in the animal health industry. Key Points and Arguments 1. **Positive Results from ASF Vaccine Trials** Bio Co., Ltd. reported successful results from its subunit ASF vaccine attack experiment, where no deaths occurred among the immunized group under an 8,000 HAD virus attack, indicating a high protection rate. This sets a solid foundation for subsequent clinical trials and approvals [2][3]. 2. **Upcoming Clinical Trials** The company plans to conduct a second attack experiment on April 12, aiming to verify the vaccine's effectiveness throughout its lifecycle. The completion of the second clinical trial is expected by late May or early June [2][3]. 3. **Market Approval Timeline** If the results are favorable, the China National Center for Animal Health (CNCA) may participate in the review process, potentially accelerating the approval timeline. The company anticipates obtaining a temporary production license by mid to late 2026, allowing for large-scale production [2][3]. 4. **Pricing Strategy** The initial pricing for the ASF vaccine is set at 25 RMB per dose, which balances affordability for farmers and the technological uniqueness of the product. The expected gross margin is projected to exceed 50%, indicating strong profitability potential [2][5]. 5. **Competitive Advantages** Bio Co., Ltd. is currently the only company certified by the Chinese Academy of Sciences to conduct clinical trials for the ASF vaccine, providing a significant competitive edge. The involvement of CNCA in the process is expected to expedite market entry [2][6][7]. 6. **Collaboration in Vietnam** The company is collaborating with local firms in Vietnam to promote the ASF vaccine, addressing the issue of local pig populations infected with recombinant viruses. They expect to obtain production licenses within six months and begin sales within 18 months [2][9]. 7. **Future Developments in mRNA Vaccines** Bio Co., Ltd. is also working on an mRNA vaccine for feline infectious peritonitis, projected to be launched domestically by 2028. The company is collaborating with two major U.S. pharmaceutical companies, utilizing a revenue-sharing model that could yield significant returns [3][10]. 8. **Overall Business Outlook for 2026** The company anticipates explosive growth in the ruminant service sector in 2026, driven by the ASF vaccine's market entry. The poultry business remains stable, and overall, the company expects positive trends across its various segments [3][12]. Additional Important Information - The company is currently focusing on testing the vaccine primarily for piglets, with plans for further discussions regarding its application for sows based on feedback from breeding farms [5]. - The competitive landscape includes other companies like Jinyu Biological, which has completed clinical trials but may face delays in large-scale production due to additional trial requirements [8]. - The fourth quarter's specific data on other products like swine foot-and-mouth disease vaccines is pending, but the ASF vaccine is expected to drive sales of existing products [11].

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has achieved significant recognition in the field of vaccine research and development, particularly through its subsidiary Beijing Minhui Biological Technology Co., Ltd., which recently won the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2]. Group 1: Project Recognition - The project "Key Technology Innovation and Application for Rapid Confirmation and Precise Prevention of Emerging Viral Infectious Diseases" addresses critical challenges in the prevention and control of new viral infectious diseases [1]. - The project was led by the Jiangsu Provincial Center for Disease Control and Prevention and nominated by the Provincial Health Commission, highlighting the importance of collaboration in public health initiatives [1]. Group 2: Vaccine Development - Minhui Biological's independently developed inactivated virus vaccine platform is a core component of the project, receiving high recognition for its innovation, practicality, and scientific value [2]. - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent inactivated enterovirus vaccines, with the quadrivalent vaccine currently in Phase I clinical trials [2]. - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2]. Group 3: Strategic Implications - The recent award is seen as a validation of the company's commitment to independent innovation and its comprehensive strength in vaccine research and development, which is expected to enhance its core competitiveness and influence in the market [2]. - Successful development of these vaccines could further enrich the company's multi-valent vaccine portfolio, solidifying its market position and providing a strong foundation for sustainable growth [2].

Core Viewpoint - The company Zhifei Biological (300122.SZ) has received approval from the National Medical Products Administration for clinical trials of its recombinant herpes zoster vaccine ZFA01 in individuals aged 40 and above, marking a significant advancement in its vaccine development efforts [1] Group 1: Vaccine Development - The recombinant herpes zoster vaccine ZFA01, developed by the company's wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice (Notice No. 2026LP00366) [1] - The vaccine utilizes a novel adjuvant developed in-house, which is expected to stimulate both cellular and humoral immune responses, potentially enhancing the vaccine's protective efficacy [1] Group 2: Market Position and Product Portfolio - As of the announcement date, there are only two approved herpes zoster vaccines available in the domestic market, indicating a competitive opportunity for the company [1] - The approval of the clinical trial application is a result of the company's focus on innovation and strengthening its core technology, which may enrich its adult vaccine offerings and enhance its market position [1]

（记者 王瀚黎） 沃森生物（300142.SZ）2月9日在投资者互动平台表示，公司四价流脑结合疫苗目前处于III期临床研究 阶段，公司将严格按照国家药品注册程序和要求的有关规定开展相关工作。 每经AI快讯，有投资者在投资者互动平台提问：贵司四价流脑结合疫苗的 Ⅲ 期临床总结报告是否已完 成全部复核工作？是否存在影响申报的临床数据问题？ ...